The mission of the Knowledge Transfer Unit (KTU) at ICMAB is to translate the ICMAB research into social use via technology and knowledge transfer, through a process which provides social and economic benefits to the ICMAB, the Industry and the society.
We are approaching a quality improvement of our technology transfer processes, especially for new marketing opportunities of our research results. Following the KTU improvement plan developed in 2018, we have increased our Human Resources by incorporating new experts with strategic capabilities, especially in IP and Public-Private-Projects and International Technology Transfer issues.
To date we have filed and licensed a significant number of patents, we are responsible of advising our researchers in IPR related matters, and encouraging them to participate in technology transfer activities.
The Knowledge Transfer Unit is formed in 2020 by Susana Garelik, Alfonso del Rey and Luis Sedano.
Total Income: 353.500€
15 new contracts have been signed, with a total budget of 177,000€:
Some companies are not listed for confidentiality reasons.
Seed Assesment Projects: 60.000€
Indústria del Coneixement (AGAUR): 3 LLAVOR projects awarded with an amount of 20,000 € each.
Other Assessment Projects: 90.000 €
CIBER-BBN: 2 assesment projects awarded with an amount of 45.000 € each.
Scientific Technological Services: 26.500 €
Other collaborations with companies:
Non Disclosure Agreement (NDAs) and Material Transfer Agreement (MTAs) contracts signed: 19
Inventors: Imma Ratera, Judith Guasch, Eduardo Pérez, Jaume Veciana, Marc Martínez, Xavier Rodríguez, Roberto Fabiao Santos, Miguel Ángel Mateos, Elisabeth Engel,
IPR holders: CSIC, UPC, IBEC, CIBER-BBN
Immunotherapy offers a different approach than standaritulld surgery, radiation and chemotherapy procedures against cancer. It is based on employing and reinforcing the immune system of patients, surpassing cancer immunosuppression methods, detecting and eliminating malignant cells without damaging healthy tissues.
Adoptive cell therapy (ACT), a type of personalized immunotherapy that has achieved complete remissions of advanced cancer patients, requires large expansions of immune cells, in order to have relevant quantities of therapeutic cells to be used as “alive drugs”. The implementation of these therapies to the clinics is limited by the current cell expansion methods.
The mimetic lymph nodes, which are based on a 3D scaffold made of a loadable PEG heparin Hydrogel with immune-relevant molecules, provide higher cell proliferation rates and capacity to tune the obtained phenotypes than the gold standard
Inventors: Mariano Campoy, Aleksandr Perevedentsev
IPR holder: CSIC
A new method for high resolution structural and/or compositional modification in a molecular organic semiconductor film. This method has applications in the production of electronic, optoelectronic and photonic devices.
A key part of fabrication of organic semiconductor active layers involve spatial patterning of material characteristics to enable device-specific functionalities.
The method consists on the solution deposition of a molecular gate interlayer onto the target semiconductor layer, followed by a donor layer comprising functional small molecules. Application of a stimulus such as laser light, activates diffusion of the functional molecules into the semiconductor layer through the molecular gate.
MATERPLAT (Plataforma Temática de Materiales)
MATERPLAT promotes Industrial Challenges and involvement through Calls and Tenders and EU levels acting as a R&D/Techno Spanish lobby on particular in Materials for Energy and Smart Cities ICMAB is not itself MATERPLAT Associate and involves in MATERPLAT through general CSIC Membershipping and LS relationships. KTT (LS) attends regularly to MATERPLAT “Asamblea” and Regular Meetings (3 events in 2020).
MATERPLAT show a clearly developed strategic capability to project Industrially Oriented Material Research and lobby on the Administration key Bodies (Ministry, CDTI). As relevant MATERPLAT (Energy Group) published the “Actualización de la Estrategia Tecnológica de Materiales Avanzados y Nanomateriales “. KTT (LS) has performed an analysis on this Strategy.
The Science Industry sector is made up of the organizations dedicated to the conception, design, construction, operation and maintenance of scientific facilities and instruments in any field. INDUCIENCIA is a structured forum, led by the industry, in which all interested agents: companies, universities, scientific centers and technological centers participate and collaborate, to jointly define the objectives of research and technological development in the medium and long term, with a clear market orientation. It contributes to the advancement of science and technology and the strengthening of technological innovation and constitutes a growing market, generator and user of new technologies, intensive in R&D and in which the transfer of knowledge and experiences is bidirectional and constant among the innovative agents.
Luis Sedano has been involved all along 2020 in INDUCIENCIA Platform (Plataforma Española de Industria de la Ciencia, managed by INEUSTAR). INDUCIENCIA involvement appears of major interest for ICMAB according to size and scope of its activities (Big Science Projects). ICMAB participation in INDUCIENCIA meetings was reported in detail to ICMAB Direction.
CMAV (ADVANCED MATERIALS CLUSTER)
CLUSTER MAV is a public-private technological regional platform with industrial oriented approach in where it results commonly challenging how to project low TRL/BRL activities.
ICMAB is an active member in the Cluster MAV. ICMAB/KTT, Luis Sedano (LS), attends regularly to FORUMs and involves in the Assembly, receives and comments the Edition of CLUSTERMAV monthly Bulletin (Butlletí d Activitats). Attendance to 5 Meetings along 2020.
Active participation in the Nanomaterials Work Group l, and specifically in the Nanohub Platform Project (Alfonso del Rey, AdR). The Nanohub platform will be the place to find equipment and services related with nanotechnology that members of the CMAV can offer. Presentation in the “TechMat breakfast: nanotechnology and potential application sectors” on March 11th.
ICMAB is an active member of SECPHO. During the last years, SECPHO has become a leading stakeholder in Technology Transfer within the so called DeepTech TT sector. SECPHO manages an interesting PHOTONICS Career Hub. During 2020, KTT offered a presentation in the Who is Who Session on 3/4/2020 (AdR), and (LS) attended to 6 meetings on diverse subjects under the ICMAB´s scoping interest.
Some of our researchers also participate in the following Technolgy Platforms:
Open Innovation Forum
ICMAB participated in the industrial challenges committee in the 2020 edition. ICMAB researchers had several meetings with companies to discuss their challenges and possible solutions. OIF has the interest of local proximity and is reorganizing and setting-up a new communication platform in the form of others existing (SECPHO, MAV, MATERPLAT).
Technology Transfer interviews
The KTT interviewed some researchers about their research related with technology transfer. The interviews (text and/or video) are found on the Industry website:
Brokerage events attendance:
Due to the COVID-19 pandemic, many events were cancelled during 2020, although many of them were virtual.
Nanomol Technologies, S.L. delivers advanced solutions to obtain high-added value products by particle technologies and nanoformulation. We offer our Proprietary Platforms for the formulation of innovative functional materials, together with advanced cGMP particle characterization services.
Nanomol Technologies was Founded in 2010 by academic researchers from Materials Science Institute of Barcelona — CSIC, having wide expertise and recognized excellence in the synthesis, processing, and study of molecular functional materials.
Located in the Barcelona Autonomous University Research Park, Nanomol is provided with excellent interaction with scientific technical services, academic research groups and biotech, pharmaceutical and chemical companies. Nanomol Technologies has developed and commercializes DELOS proprietary platforms, useful to innovate, develop or improve new and existing products in areas like pharmaceuticals, cosmetics, biocides and medical devices.